

**REMARKS**


In response to the Examiner's notice to comply as set forth in 37 C.F.R. 1.821-1.825, Applicants have provided a substitute computer readable form (CFR) copy of the "sequence listing," substitute paper copy of the "sequence listing," as well as, an amendment directing its entry into the specification.

Applicants further ensure that the contents of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or (1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

This paper is being filed timely as a request for a three month extension of time is filed concurrently herewith. No additional extensions of time are required. In the event any additional extensions of time are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

<u>January 22, 2003</u>	<p>MILLENNIUM PHARMACEUTICALS, INC.</p> <p>By </p> <p>Theodore Allen Registration No. 41,578 75 Sidney Street Cambridge, MA 02139 Telephone - 617-761-6815 Facsimile - 617-374-0074</p>
-------------------------	---

**RECEIVED**

JAN 30 2003

Attorney's Docket No. 10448-061001(MPI2000-252P1RM)

TECH CENTER 1600/2900

**Exhibit A: Version With Markings To Show Changes Made**

**Please amend page 9 Figure 4C without prejudice or disclaimer to read as follows:**

Figure 4C-D depicts an alignment of the amino acid sequence of human 33408 (upper sequence; SEQ ID NO: 5) with the amino acid sequence of rat Eag2 (lower sequence; Accession Number AF185637; SEQ. ID NO:12).